However, in a subsequent phase II TRINITY study for SCLC patients with multiple prior treatments (NCT02674568), the ORR was lower at 12.4% in all participants, 14.3% with ≥25% of tumor cells positive for DLL3, and 13.2% with ≥75% of tumor cells positive for DLL3, respectively.277. This evidence concerns the gene DLL3 and neoplasm.